Transcript
Dr. Neal Bhatia: When we think about treatment cycling, what does that really mean to the dermatologist? Because again, with plaque psoriasis, we think about maybe class shifting, or we may go from biologic to oral to including topicals. That's an obvious transition that we are used to, but treatment cycling in psoriatic arthritis, what does that mean to you?
Dr. Lourdes Perez-Chada: Well, when we think about the treatment for psoriatic arthritis, we really have to think about what domains are affected. I'm following here mostly the GRAPPA guidelines, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis, which take an approach that we should try to cover as many affected domains of psoriatic arthritis as possible when thinking about treatment. Depending on where you are located geographically, your country and regulatory agencies may mandate how you have to start treatment, whether you have to start, for example, with methotrexate, have it fail, and then move on to biologics, or not, here in the U.S. at least. What the GRAPPA guidelines also support is that you don't necessarily have to fail that first conventional systemic DMARD, such as methotrexate, to be able to prescribe a biologic directly if you think it's appropriate to do so.
Dr. Neal Bhatia: That's interesting because there's a patient-driven effect to say that I'm not responding, and then there's the dermatologist's assessment that says the patient's not responding, and the rheumatologist, of course. I mean, is there something that tells anybody that we're losing response? Is there something else, obviously outside of a tolerable treatment or a convenient dosage schedule or insurance access? Are there any other factors that would cause patients to say, "Let's rotate therapies or move on to something else?"
Dr. Lourdes Perez-Chada: When a patient is not responding, first you have to distinguish whether it's a primary nonresponse or loss of efficacy. The research that has been done is trying to understand whether there is a preference when cycling therapies, right? So there are maybe two things worth distinguishing, which are cycling within a medication class and switching. There are studies trying to see whether there is any benefit to cycling within a certain class, for example, within anti-TNFs when a patient is not responding to the first one. That's where the question of whether it's a primary nonresponse versus a secondary loss becomes important, right? If a patient is on an anti-TNF and doesn't respond on the first attempt, trying a second one is possible, but maybe you want to think about switching or swapping to a different mechanism instead of cycling within the same family of agents, right?
Dr. Neal Bhatia: Yeah.
Dr. Lourdes Perez-Chada: As compared to when you are going with your second, for example, you start off with a TNF, it worked well, but then you lose response. Let's say you started with etanercept or adalimumab and you lost response. It wouldn't be crazy to think, "Why don't we try, for example, infliximab?" Maybe by tailoring it more for this patient, we will have a better response, particularly in psoriatic arthritis, where TNFs are so important because they perform pretty comparably to other agents, right? So cycling happens, it's relevant, it's important, and in certain patients and characteristics, it's still prevalent. But then we're observing that there's now a lot of switching or swapping to a different medication class, such as, for example, IL-17s.
The studies that have been done comparing outcomes in terms of drug persistence or response, in terms of remission or low disease activity in psoriatic arthritis, do not necessarily show that cycling within a specific family of medications versus swapping or switching is better. The data are contradictory. It depends on so many variables. Many of these studies are done with observational data, right? And so when you see that, for example, the persistence of a drug in a certain population lasted, let's say, 12 months, and in another study it lasted six months or so, it really depends on what that initial population in those studies looked like and the reasons why a medication was stopped. Sometimes it's access, sometimes it's an adverse event, and sometimes it's lack of efficacy, right? So we have to understand these data through that lens, if that makes sense.
Dr. Neal Bhatia: Yeah. And that's an important concept because we don't consider persistence as something that we should be taking into account for long-term management, or is there some other element that drives persistence? If you think about a patient persisting on a therapy, but we are looking at their mechanism, when is longer persistence better correlated with efficacy, or is there something that we are maybe having to think about further into the course? Because if there's a comfort level on the part of the physician and we don't see them back, is that something that maybe we should be doing a little bit less often?
Dr. Lourdes Perez-Chada: It's interesting that you mentioned persistence in terms of efficacy. I don't think I've seen so much data in that respect particularly, right? I don't see that question having been answered so clearly, but there are other things with regard to treatment that are important to highlight. For example, more important than the length of time on therapy in observing good remission or low disease activity outcomes is the time at which you initiate that treatment. So maybe something that's important to highlight for dermatologists, and why we want to refer all these patients who are at higher risk to a rheumatologist early on, is that we know that at least six months of delay in a patient who has psoriatic arthritis is going to impact the functional outcomes in that patient and overall outcomes. So we want to avoid having more than a six-month delay in diagnosing these patients to preserve their function.
Dr. Neal Bhatia: Yeah.
Dr. Lourdes Perez-Chada: And also, sorry, this is reflected through changes in radiographic imaging. In this particular study, what they observed was erosions in those patients who were diagnosed after six months.
